Ruxolitinib (Topical)

Ruxolitinib (Topical) Uses, Dosage, Side Effects, Food Interaction and all others data.

Ruxolitinib (Topical)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ruxolitinib (Topical)
Generic	Ruxolitinib (Topical)
Type
Therapeutic Class	Pyrrolopyrimidines
Manufacturer
Available Country	Bangladesh
Last Updated:	September 24, 2024 at 5:38 am

Uses

Atopic Dermatitis: Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dosage

Ruxolitinib (Topical) dosage

Apply thin layer of cream to affected areas BID of up to 20% body surface area; not to exceed >60 g/week. It should stop using when signs and symptoms (eg, itch, rash, redness) of atopic dermatitis resolve. If signs and symptoms do not improve within 8 weeks, re-examine patient. Or, as directed by the registered physician.

Side Effects

Side effects of Ruxolitinib cream are Nasopharyngitis (3%), Bronchitis (1%), Ear infection (1%), Eosinophil count increased (1%), Urticaria (1%), Diarrhea (1%), Folliculitis (1%), Tonsillitis (1%), Rhinorrhea (1%).

Precaution

Serious infections: i) Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens reported with oral JAK inhibitors, ii) Serious lower respiratory tract infections reported in the clinical development program with topical Ruxolitinib. Viral reactivation: Viral reactivation, including cases of herpes virus reactivation (eg, herpes zoster), were reported with JAK inhibitors used to treat inflammatory conditions. Hepatitis B and C: i) Impact of JAK inhibitors used to treat inflammatory conditions on chronic viral hepatitis reactivation is unknown, ii) Patients with history of hepatitis B or C infection were excluded from clinical trials.

Interaction

Drug interaction studies were not conducted Ruxolitinib is a substrate of CYP3A4 Strong CYP3A4 inhibitors Avoid coadministration Strong CYP3A4 inhibitors may increase ruxolitinib systemic exposure and adverse reactions